Presentations—Expert Insights on Contemporary Issues in MM - priME Oncology
prIME Downloadable Slides
prIME Downloadable Slides

Presentations—Expert Insights on Contemporary Issues in MM

An Interactive Symposium

View Activities

Not a member of My prIME? Join now for instant access.

The information in this activity is intended for healthcare professionals based outside of the United States. You will be asked to provide your credentials before participating in the activity. This activity may contain information on products outside the approved indications where you practice.

With these downloadable slides presented at our symposium held at the 23rd Congress of the European Hematology Association, explore the latest updates on the treatment of patients with relapsed/refractory multiple myeloma (R/R MM) discussing the whole landscape from diagnosis to penta-refractory MM.

Downloadable Slides

Downloadable Slides

Release Date

Release Date

Jun 17, 2018

Expiration Date

Jun 17, 2019

Featured Expert

  • Michele Cavo, MD, University of Bologna, Bologna, Italy

Featured Topic

Initial therapy for transplant-eligible patients with MM

Featured Expert

  • Jesús San Miguel, MD, PhD, Universidad de Navarra, Pamplona, Spain

Featured Topic

Initial therapy for transplant-ineligible patients with MM

Featured Expert

  • Meletios Dimopoulos, MD, University of Athens, Athens, Greece

Featured Topic

Relapsed MM

Featured Expert

  • Sagar Lonial, MD, Winship Cancer Institute, Emory University, Atlanta, Georgia, United States

Featured Topic

Strategies in tertiary-, quad-, and penta-refractory MM

Featured Expert

  • Jesús San Miguel, MD, PhD, Universidad de Navarra, Pamplona, Spain

Featured Topic

Closing remarks

This educational activity is designed for hematologists, medical oncologists, and other healthcare professionals involved in the management of patients with MM.

After successful completion of this educational activity, participants should be able to:

  • Apply recent data from trials of front-line therapy for transplant-eligible patients with MM into clinical practice
  • Identify optimal strategies for initial therapy of transplant-ineligible patients with MM
  • Incorporate potential adverse events of therapeutic agents into the selection of therapy for R/R MM in individual patients
  • Describe novel therapies with demonstrated efficacy in patients who have had 4-6 prior lines of therapy for R/R MM

This educational activity is supported by Celgene and Karyopharm Therapeutics.

Enduring Materials From a Certified Activity

This enduring material, derived from a certified live event, contains content that is evidence-based, balanced, and free of commercial bias. While the content was planned and implemented by prIME Oncology for a certified live event, this activity does not offer continuing education credit.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Disclosure of Relevant Financial Relationships

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Cavo has disclosed that he has received honoraria or consultation fees from Amgen, Bristol-Myers Squibb, Celgene, Janssen, Novartis, and Takeda. He has also participated in company-sponsored speaker’s bureaus for Amgen, Celgene, Janssen, and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Dimopoulos has disclosed that he has received honoraria or consultation fees from Amgen, Celgene, Janssen, and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Lonial has disclosed that he has received honoraria or consultation fees from Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Merck, Novartis, and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr San Miguel has disclosed that he has received honoraria or consultation fees from Amgen, Bristol-Myers Squibb, Celgene, Janssen, MSD, Novartis, Roche, Sanofi, and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Janice Galleshaw, MD (medical director content reviewer/planner) – no relevant financial relationships
  • Sanneke Koekkoek, RN (scientific content reviewer/planner) –no relevant financial relationships
  • Trudy Stoddert, ELS (editorial content reviewer) –no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.